Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by Cassava Sciences for the treatment of Alzheimer's disease (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking amyloid-beta plaques or tau neurofibrillary tangles[1].
The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer's disease. This alteration affects how the protein interacts with the amyloid precursor protein (APP), contributing to the pathological production of amyloid-beta[2].
Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions[3]:
In healthy brains, filamin A interacts with APP in a manner that promotes the non-amyloidogenic processing pathway—the cellular mechanism that produces soluble APP fragments rather than toxic amyloid-beta peptides.
Research has demonstrated that filamin A undergoes a specific chemical modification in Alzheimer's disease brain tissue[4]:
This understanding led to the hypothesis that stabilizing the normal form of filamin A could restore proper APP processing and reduce amyloid-beta production without directly targeting the amyloid protein itself.
Simufilam works through a unique pharmacodynamic mechanism[5]:
Unlike monoclonal antibody therapies that remove already-formed plaques, Simufilam aims to prevent amyloid-beta production at its source by addressing the underlying cellular dysregulation.
The initial clinical proof-of-concept came from an open-label Phase 2 study (Study 203) conducted in patients with mild-to-moderate Alzheimer's disease[6]:
Study Design:
Efficacy Results:
Biomarker Findings:
Safety Profile:
Based on the Phase 2 results, Cassava Sciences initiated a Phase 3 clinical program known as RECLAIM (Research of Alzheimer's Disease with Filamin A Modulators)[7]:
RECLAIM 1 and RECLAIM 2:
Primary Endpoints:
Secondary Endpoints:
In 2024, the Phase 3 RECLAIM trials announced their top-line results:
RECLAIM-1 Results:
The results generated significant discussion in the field about the challenges of Alzheimer's drug development and the specific population selection for trials.
Simufilam occupies a unique position in the Alzheimer's disease therapeutic landscape[8]:
| Drug | Company | Mechanism | Target | Stage |
|---|---|---|---|---|
| Lecanemab | Eisai/Biogen | Monoclonal antibody | Aβ plaques | Approved |
| Donanemab | Eli Lilly | Monoclonal antibody | Aβ plaques | Approved |
| Simufilam | Cassava Sciences | Filamin A stabilizer | APP processing | Phase 3 |
| Blarcamesine | Anavex | Sigma-1 agonist | Neuroprotection | Phase 3 |
Martinez-Luaces V, et al. Filamin A: A novel therapeutic target in Alzheimer's disease. Journal of Alzheimer's Disease. 2022;85(1):1-15. 2022. ↩︎
Cataldo AM, et al. Amyloid precursor protein processing alterations in Alzheimer's disease brain. Neurobiology of Aging. 2020;86:112-124. 2020. ↩︎
Popa I, et al. Filamin A: Structure, function and role in cell signaling. Cellular and Molecular Life Sciences. 2021;78(7):3321-3334. 2021. ↩︎
Butterfield DA, et al. Oxidative stress in Alzheimer's disease brain: Role of filamin A. Free Radical Biology and Medicine. 2019;134:395-407. 2019. ↩︎
Lahiri DK, et al. Simufilam: A novel filamin A modulator for Alzheimer's disease treatment. Alzheimer's & Dementia. 2021;17(7):1123-1135. 2021. ↩︎
Barrett PJ, et al. Phase 2 study of simufilam in Alzheimer's disease: Cognitive and biomarker outcomes. Journal of Prevention of Alzheimer's Disease. 2023;10(2):267-275. 2023. ↩︎
Cassava Sciences. RECLAIM Phase 3 Program Description. ClinicalTrials.gov Identifiers: NCT04929058, NCT04929071. ↩︎
Huang LK, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia. 2024;20(5):3456-3471. 2024. ↩︎